Achim Wöckel1, L Schwentner2, M Krockenberger3, R Kreienberg4, W Janni2, M Wischnewsky5, Kühn Thorsten6, Flock Felix7, Felberbaum Riccardo8, M Blettner9, S Singer9. 1. Department of Obstetrics and Gynecology, Würzburg University Hospital, Würzburg, Germany. Markert_F@ukw.de. 2. Department of Obstetrics and Gynecology, Ulm University Hospital, Ulm, Germany. 3. Department of Obstetrics and Gynecology, Würzburg University Hospital, Würzburg, Germany. 4. , Landshut, Germany. 5. eScience lab, University Bremen, Bremen, Germany. 6. Department of Obstetrics and Gynecology, Esslingen Hospital, Esslingen am Neckar, Germany. 7. Department of Obstetrics and Gynecology, Memmingen Hospital, Memmingen, Germany. 8. Department of Obstetrics and Gynecology, Clinic of Kempten, Academic Teaching Hospital - University of Ulm, Ulm, Germany. 9. Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Centre, Mainz, Germany.
Abstract
PURPOSE: Multimodal therapies affect the quality of life (QoL) of patients with primary breast cancer (PBC). The objectives of this prospective study were to explore the changes in QoL from diagnosis to conclusion of adjuvant therapy and to identify predictive factors of QoL. METHODS: Before surgery (t1), before onset of adjuvant treatment (t2) and after completion of adjuvant chemo- or radiotherapy (t3), patients with PBC (n = 759) completed the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire, Charlson Comorbidity Index, Patient Health Questionnaire and Perceived Involvement in Care Scales. Predictors of the course of global QoL were estimated using multinomial logistic regression. Effect estimates are odds ratios (OR) and their 95% confidence intervals (CIs). RESULTS: Global QoL improved between t1 and t3, while physical functioning, emotional functioning and fatigue deteriorated. QoL before surgery was more often poor in patients <60 years (OR 2.2, 95% CI 1.5-3.1) and in those with comorbid mental illnesses (OR 8.6, CI 5.4-13.7). Forty-seven percentage reported good global QoL both at t1 and at t3. QoL improved in 28%, worsened in 10% and remained poor in 15%. Compared to patients with consistently good global QoL, a course of improving QoL was more often seen in patients who had received a mastectomy and in those with intense fear of treatment before surgery. A course of decreasing QoL was more often found in patients who were treated with chemotherapy. QoL stayed poor in patients with chemotherapy, mastectomy and intense fear. There was no evidence that radiotherapy, progressive disease or perceived involvement impact the course of QoL. CONCLUSIONS: Younger age and comorbid mental illnesses are associated with poor QoL pre-therapeutically. QoL is more likely to stay or become poor in patients who receive chemotherapy.
PURPOSE: Multimodal therapies affect the quality of life (QoL) of patients with primary breast cancer (PBC). The objectives of this prospective study were to explore the changes in QoL from diagnosis to conclusion of adjuvant therapy and to identify predictive factors of QoL. METHODS: Before surgery (t1), before onset of adjuvant treatment (t2) and after completion of adjuvant chemo- or radiotherapy (t3), patients with PBC (n = 759) completed the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire, Charlson Comorbidity Index, Patient Health Questionnaire and Perceived Involvement in Care Scales. Predictors of the course of global QoL were estimated using multinomial logistic regression. Effect estimates are odds ratios (OR) and their 95% confidence intervals (CIs). RESULTS: Global QoL improved between t1 and t3, while physical functioning, emotional functioning and fatigue deteriorated. QoL before surgery was more often poor in patients <60 years (OR 2.2, 95% CI 1.5-3.1) and in those with comorbid mental illnesses (OR 8.6, CI 5.4-13.7). Forty-seven percentage reported good global QoL both at t1 and at t3. QoL improved in 28%, worsened in 10% and remained poor in 15%. Compared to patients with consistently good global QoL, a course of improving QoL was more often seen in patients who had received a mastectomy and in those with intense fear of treatment before surgery. A course of decreasing QoL was more often found in patients who were treated with chemotherapy. QoL stayed poor in patients with chemotherapy, mastectomy and intense fear. There was no evidence that radiotherapy, progressive disease or perceived involvement impact the course of QoL. CONCLUSIONS: Younger age and comorbid mental illnesses are associated with poor QoL pre-therapeutically. QoL is more likely to stay or become poor in patients who receive chemotherapy.
Entities:
Keywords:
EORTC QLQ-C30; Emotional functioning; Fear of therapy; Physical functioning; Primary breast cancer; Quality of life
Authors: Martine M Goedendorp; Michael A Andrykowski; Kristine A Donovan; Heather S Jim; Kristin M Phillips; Brent J Small; Christine Laronga; Paul B Jacobsen Journal: Cancer Date: 2011-11-15 Impact factor: 6.860
Authors: R Navinés; P Castellví; J Moreno-España; D Gimenez; M Udina; S Cañizares; C Diez-Quevedo; M Valdés; R Solà; R Martín-Santos Journal: J Affect Disord Date: 2012-02-10 Impact factor: 4.839
Authors: Kristin Härtl; Jutta Engel; Peter Herschbach; Hans Reinecker; Harald Sommer; Klaus Friese Journal: Psychooncology Date: 2010-02 Impact factor: 3.894
Authors: Saskia F A Duijts; Martine P van Egmond; Evelien Spelten; Peter van Muijen; Johannes R Anema; Allard J van der Beek Journal: Psychooncology Date: 2013-12-23 Impact factor: 3.894
Authors: Daniel S J Costa; Rebecca Mercieca-Bebber; Claudia Rutherford; Margaret-Ann Tait; Madeleine T King Journal: Qual Life Res Date: 2021-04-01 Impact factor: 4.147
Authors: Jennifer J Hu; James J Urbanic; L Doug Case; Cristiane Takita; Jean L Wright; Doris R Brown; Carl D Langefeld; Mark O Lively; Sandra E Mitchell; Anu Thakrar; David Bryant; Kathy Baglan; Jon Strasser; Luis Baez-Diaz; Glenn J Lesser; Edward G Shaw Journal: J Clin Oncol Date: 2018-07-10 Impact factor: 44.544
Authors: Magdalena Konieczny; Elżbieta Cipora; Wojciech Roczniak; Magdalena Babuśka-Roczniak; Marek Wojtaszek Journal: Int J Environ Res Public Health Date: 2020-11-11 Impact factor: 3.390
Authors: Patricia Lindberg-Scharf; Brunhilde Steinger; Michael Koller; Andrea Hofstädter; Olaf Ortmann; Jan Kurz; Jonathan Sasse; Monika Klinkhammer-Schalke Journal: Support Care Cancer Date: 2021-06-27 Impact factor: 3.603